Have a feature idea you'd love to see implemented?
Let us know!
DTIL Precision Biosciences Inc
Price (delayed)
$6.5
Market cap
$49.86M
P/E Ratio
34.21
Dividend/share
N/A
EPS
$0.19
Enterprise value
-$41.16M
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome
Highlights
Precision Biosciences's quick ratio has surged by 151% QoQ
The company's equity has surged by 123% YoY but it fell by 13% QoQ
The company's net income has surged by 112% YoY but it fell by 49% QoQ
Key stats
What are the main financial stats of DTIL
Market
Valuations
Earnings
Shares outstanding
7.67M
Market cap
$49.86M
Enterprise value
-$41.16M
Price to earnings (P/E)
34.21
Price to book (P/B)
0.72
Price to sales (P/S)
0.63
EV/EBIT
-3.89
EV/EBITDA
-2.58
EV/Sales
-0.55
Revenue
$75.1M
EBIT
$10.59M
EBITDA
$15.97M
Free cash flow
-$48.22M
Per share
Balance sheet
Liquidity
EPS
$0.19
Free cash flow per share
-$6.62
Book value per share
$8.97
Revenue per share
$10.31
TBVPS
$20.98
Total assets
$153.26M
Total liabilities
$88.39M
Debt
$30.31M
Equity
$64.87M
Working capital
$98.54M
Debt to equity
0.47
Current ratio
9.22
Quick ratio
10.35
Net debt/EBITDA
-5.7
Margins
Efficiency
Dividend
EBITDA margin
21.3%
Gross margin
100%
Net margin
11.5%
Operating margin
-21.6%
Return on assets
5.2%
Return on equity
17.6%
Return on invested capital
37.5%
Return on capital employed
7.5%
Return on sales
14.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DTIL stock price
How has the Precision Biosciences stock price performed over time
Intraday
-9.47%
1 week
-15.58%
1 month
-26.3%
1 year
-48.37%
YTD
-40.64%
QTD
-27.46%
Financial performance
How have Precision Biosciences's revenue and profit performed over time
Revenue
$75.1M
Gross profit
$75.1M
Operating income
-$16.21M
Net income
$8.62M
Gross margin
100%
Net margin
11.5%
The operating margin has dropped by 160% since the previous quarter but it has soared by 72% year-on-year
DTIL's operating income has shrunk by 122% QoQ but it has soared by 60% YoY
The company's net income has surged by 112% YoY but it fell by 49% QoQ
DTIL's net margin has soared by 108% YoY but it is down by 41% QoQ
Growth
What is Precision Biosciences's growth rate over time
Valuation
What is Precision Biosciences stock price valuation
P/E
34.21
P/B
0.72
P/S
0.63
EV/EBIT
-3.89
EV/EBITDA
-2.58
EV/Sales
-0.55
DTIL's EPS has soared by 101% year-on-year but it is down by 44% since the previous quarter
The company's equity has surged by 123% YoY but it fell by 13% QoQ
DTIL's P/B is 81% below its 5-year quarterly average of 3.8 and 58% below its last 4 quarters average of 1.7
The P/S is 92% lower than the 5-year quarterly average of 7.6 and 30% lower than the last 4 quarters average of 0.9
Precision Biosciences's revenue has increased by 44% YoY but it has decreased by 14% from the previous quarter
Efficiency
How efficient is Precision Biosciences business performance
Precision Biosciences's ROA has soared by 114% YoY but it has decreased by 49% from the previous quarter
Precision Biosciences's return on equity has surged by 110% YoY but it has shrunk by 59% QoQ
DTIL's ROS has soared by 110% year-on-year but it is down by 36% since the previous quarter
The return on invested capital has surged by 103% year-on-year but it has dropped by 73% since the previous quarter
Dividends
What is DTIL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DTIL.
Financial health
How did Precision Biosciences financials performed over time
Precision Biosciences's total assets is 73% more than its total liabilities
Precision Biosciences's quick ratio has surged by 151% QoQ
DTIL's current ratio has surged by 111% since the previous quarter
DTIL's debt is 53% lower than its equity
The company's equity has surged by 123% YoY but it fell by 13% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.